CASE REPORT: SPECIFIC ABL-INHIBITOR IMATINIB IS AN EFFECTIVE TARGETED AGENT AS THE FIRST LINE THERAPY TO TREAT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A CRYPTIC NUP214::ABL1 GENE FUSION

Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI).NUP214::ABL1 fusion is detected in 6% of T-cell acute lymphoblastic leukemia (T-ALL), and is very rare in B-ALL.We present a c

Diego Novick,1 William Montgomery,2 Zbigniew Kadziola,3 Victoria Moneta,4 Xiaomei Peng,5 Roberto Brugnoli,6 Josep Maria Haro41Eli Lilly and Company, Windlesham, Surrey, UK; 2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 3Eli Lilly Austria GmbH, Vienna, Austria; 4Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Dé

Background: Blood-feeding arthropods support a diverse array of symbiotic microbes, some of which facilitate host growth and development whereas others are detrimental to vector-borne pathogens.We found a common core constituency among the microbiota 310.32.42.50.01.001 of 16 different arthropod blood-sucking disease vectors, including Bacillaceae,

Methadone maintenance treatment (MMT) is aimed to reduce the harmful effects of injecting drug use.Since the first Puskesmas Poncol opened this program in 2010, there were 50 users of MMT.Currently users of MMT were 11 people, 2 people have died, no patient has recovered, and 36 others dropped fume mini flavors out.Those did not recover, but droppe